Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $246 | $279 | $211 | $211 |
| - Cash | $40 | $54 | $103 | $161 |
| + Debt | $14 | $17 | $19 | $2 |
| Enterprise Value | $220 | $243 | $128 | $52 |
| Revenue | $0 | $33 | $5 | $2 |
| % Growth | -99.3% | 579.2% | 146.3% | – |
| Gross Profit | $0 | $33 | $5 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$65 | -$28 | -$59 | -$72 |
| % Margin | -25,837.1% | -84.8% | -1,189.8% | -3,575.3% |
| Net Income | -$58 | -$28 | -$58 | -$72 |
| % Margin | -23,304% | -82.7% | -1,184.1% | -3,587.7% |
| EPS Diluted | -5.2 | -1.19 | -3.32 | -4.08 |
| % Growth | -337% | 64.2% | 18.6% | – |
| Operating Cash Flow | -$55 | -$47 | -$51 | -$15 |
| Capital Expenditures | -$1 | -$3 | -$6 | -$2 |
| Free Cash Flow | -$56 | -$51 | -$57 | -$17 |